-100%

est. 2Y upside i

HealthcareSeries D+

Blood testing device for early diagnosis of cancer and treatment…

Rank

#3836

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Delee has minimal revenue ($55.6k) and faces a dominant incumbent (CellSearch), high regulatory barriers, and a preference stack that fully covers the company's assumed valuation.

Last updated: July 3, 2026

Bull (10%)-100%

Even with FDA approval and revenue growth, exit value remains below total funding due to tiny revenue base, resulting in zero common recovery.

Base (45%)-100%

Revenue stagnant due to no commercial traction; exit multiple compresses to 4x, implying enterprise value of $222k, well below $4M preference.

Bear (45%)-100%

Incumbent CellSearch dominance and regulatory delays lead to minimal revenue; exit multiple at 2x yields $111k, common stock worthless.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

10000%

Total funding of $4.08M equals the assumed entry valuation, creating 100% preference overhang; common stock is underwater even at current valuation.

Dilution Risk

high

With only $80k raised in the latest round and high burn rate, a dilutive down round is likely within 24 months.

Secondary Liquidity

none

No secondary market exists; no recent trades or implied valuation from secondary sources.

Questions to Ask at the Interview

Strategic questions based on Delee's data — designed to show you've done your homework.

  • 1

    “How does CytoCatch differentiate from CellSearch's FDA-approved platform in clinical adoption?”

  • 2

    “What is the company's path to FDA clearance and estimated timeline?”

  • 3

    “Given the low revenue, what is the current cash runway and expected next funding round?”

Community

Valuation Sentiment

Our model estimates -100% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.